Global Dermatomycoses Drug Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Dermatomycoses Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Dermatomycoses Drug Industry Forecast” looks at past sales and reviews total world Dermatomycoses Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Dermatomycoses Drug sales for 2025 through 2031. With Dermatomycoses Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dermatomycoses Drug industry.
This Insight Report provides a comprehensive analysis of the global Dermatomycoses Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dermatomycoses Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dermatomycoses Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dermatomycoses Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dermatomycoses Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Dermatomycoses Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Dermatomycoses Drug market?
What factors are driving Dermatomycoses Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dermatomycoses Drug market opportunities vary by end market size?
How does Dermatomycoses Drug break out by Type, by Application?
The global Dermatomycoses Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Dermatomycoses Drug Industry Forecast” looks at past sales and reviews total world Dermatomycoses Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Dermatomycoses Drug sales for 2025 through 2031. With Dermatomycoses Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dermatomycoses Drug industry.
This Insight Report provides a comprehensive analysis of the global Dermatomycoses Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dermatomycoses Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dermatomycoses Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dermatomycoses Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dermatomycoses Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Dermatomycoses Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- BB-2603
- Clotrimazole
- Dapaconazole
- Others
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Anacor Pharmaceuticals Inc
- Biolab Farmaceutica Ltda
- Blueberry Therapeutics Ltd
- Daewoong Pharmaceutical Co Ltd
- Dermala Inc
- Helix BioMedix Inc
- Novan Inc
- Sol-Gel Technologies Ltd
- TGV-Laboratories
- Viamet Pharmaceuticals Inc
- Vyome Biosciences Pvt Ltd
What is the 10-year outlook for the global Dermatomycoses Drug market?
What factors are driving Dermatomycoses Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dermatomycoses Drug market opportunities vary by end market size?
How does Dermatomycoses Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Dermatomycoses Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Dermatomycoses Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Dermatomycoses Drug by Country/Region, 2020, 2024 & 2031
2.2 Dermatomycoses Drug Segment by Type
2.2.1 BB-2603
2.2.2 Clotrimazole
2.2.3 Dapaconazole
2.2.4 Others
2.3 Dermatomycoses Drug Sales by Type
2.3.1 Global Dermatomycoses Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Dermatomycoses Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Dermatomycoses Drug Sale Price by Type (2020-2025)
2.4 Dermatomycoses Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Dermatomycoses Drug Sales by Application
2.5.1 Global Dermatomycoses Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Dermatomycoses Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Dermatomycoses Drug Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Dermatomycoses Drug Breakdown Data by Company
3.1.1 Global Dermatomycoses Drug Annual Sales by Company (2020-2025)
3.1.2 Global Dermatomycoses Drug Sales Market Share by Company (2020-2025)
3.2 Global Dermatomycoses Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Dermatomycoses Drug Revenue by Company (2020-2025)
3.2.2 Global Dermatomycoses Drug Revenue Market Share by Company (2020-2025)
3.3 Global Dermatomycoses Drug Sale Price by Company
3.4 Key Manufacturers Dermatomycoses Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Dermatomycoses Drug Product Location Distribution
3.4.2 Players Dermatomycoses Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DERMATOMYCOSES DRUG BY GEOGRAPHIC REGION
4.1 World Historic Dermatomycoses Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Dermatomycoses Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Dermatomycoses Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Dermatomycoses Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Dermatomycoses Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Dermatomycoses Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Dermatomycoses Drug Sales Growth
4.4 APAC Dermatomycoses Drug Sales Growth
4.5 Europe Dermatomycoses Drug Sales Growth
4.6 Middle East & Africa Dermatomycoses Drug Sales Growth
5 AMERICAS
5.1 Americas Dermatomycoses Drug Sales by Country
5.1.1 Americas Dermatomycoses Drug Sales by Country (2020-2025)
5.1.2 Americas Dermatomycoses Drug Revenue by Country (2020-2025)
5.2 Americas Dermatomycoses Drug Sales by Type (2020-2025)
5.3 Americas Dermatomycoses Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Dermatomycoses Drug Sales by Region
6.1.1 APAC Dermatomycoses Drug Sales by Region (2020-2025)
6.1.2 APAC Dermatomycoses Drug Revenue by Region (2020-2025)
6.2 APAC Dermatomycoses Drug Sales by Type (2020-2025)
6.3 APAC Dermatomycoses Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Dermatomycoses Drug by Country
7.1.1 Europe Dermatomycoses Drug Sales by Country (2020-2025)
7.1.2 Europe Dermatomycoses Drug Revenue by Country (2020-2025)
7.2 Europe Dermatomycoses Drug Sales by Type (2020-2025)
7.3 Europe Dermatomycoses Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Dermatomycoses Drug by Country
8.1.1 Middle East & Africa Dermatomycoses Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Dermatomycoses Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Dermatomycoses Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Dermatomycoses Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Dermatomycoses Drug
10.3 Manufacturing Process Analysis of Dermatomycoses Drug
10.4 Industry Chain Structure of Dermatomycoses Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Dermatomycoses Drug Distributors
11.3 Dermatomycoses Drug Customer
12 WORLD FORECAST REVIEW FOR DERMATOMYCOSES DRUG BY GEOGRAPHIC REGION
12.1 Global Dermatomycoses Drug Market Size Forecast by Region
12.1.1 Global Dermatomycoses Drug Forecast by Region (2026-2031)
12.1.2 Global Dermatomycoses Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Dermatomycoses Drug Forecast by Type (2026-2031)
12.7 Global Dermatomycoses Drug Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Anacor Pharmaceuticals Inc
13.1.1 Anacor Pharmaceuticals Inc Company Information
13.1.2 Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolios and Specifications
13.1.3 Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Anacor Pharmaceuticals Inc Main Business Overview
13.1.5 Anacor Pharmaceuticals Inc Latest Developments
13.2 Biolab Farmaceutica Ltda
13.2.1 Biolab Farmaceutica Ltda Company Information
13.2.2 Biolab Farmaceutica Ltda Dermatomycoses Drug Product Portfolios and Specifications
13.2.3 Biolab Farmaceutica Ltda Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Biolab Farmaceutica Ltda Main Business Overview
13.2.5 Biolab Farmaceutica Ltda Latest Developments
13.3 Blueberry Therapeutics Ltd
13.3.1 Blueberry Therapeutics Ltd Company Information
13.3.2 Blueberry Therapeutics Ltd Dermatomycoses Drug Product Portfolios and Specifications
13.3.3 Blueberry Therapeutics Ltd Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Blueberry Therapeutics Ltd Main Business Overview
13.3.5 Blueberry Therapeutics Ltd Latest Developments
13.4 Daewoong Pharmaceutical Co Ltd
13.4.1 Daewoong Pharmaceutical Co Ltd Company Information
13.4.2 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolios and Specifications
13.4.3 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Daewoong Pharmaceutical Co Ltd Main Business Overview
13.4.5 Daewoong Pharmaceutical Co Ltd Latest Developments
13.5 Dermala Inc
13.5.1 Dermala Inc Company Information
13.5.2 Dermala Inc Dermatomycoses Drug Product Portfolios and Specifications
13.5.3 Dermala Inc Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Dermala Inc Main Business Overview
13.5.5 Dermala Inc Latest Developments
13.6 Helix BioMedix Inc
13.6.1 Helix BioMedix Inc Company Information
13.6.2 Helix BioMedix Inc Dermatomycoses Drug Product Portfolios and Specifications
13.6.3 Helix BioMedix Inc Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Helix BioMedix Inc Main Business Overview
13.6.5 Helix BioMedix Inc Latest Developments
13.7 Novan Inc
13.7.1 Novan Inc Company Information
13.7.2 Novan Inc Dermatomycoses Drug Product Portfolios and Specifications
13.7.3 Novan Inc Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Novan Inc Main Business Overview
13.7.5 Novan Inc Latest Developments
13.8 Sol-Gel Technologies Ltd
13.8.1 Sol-Gel Technologies Ltd Company Information
13.8.2 Sol-Gel Technologies Ltd Dermatomycoses Drug Product Portfolios and Specifications
13.8.3 Sol-Gel Technologies Ltd Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Sol-Gel Technologies Ltd Main Business Overview
13.8.5 Sol-Gel Technologies Ltd Latest Developments
13.9 TGV-Laboratories
13.9.1 TGV-Laboratories Company Information
13.9.2 TGV-Laboratories Dermatomycoses Drug Product Portfolios and Specifications
13.9.3 TGV-Laboratories Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 TGV-Laboratories Main Business Overview
13.9.5 TGV-Laboratories Latest Developments
13.10 Viamet Pharmaceuticals Inc
13.10.1 Viamet Pharmaceuticals Inc Company Information
13.10.2 Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolios and Specifications
13.10.3 Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Viamet Pharmaceuticals Inc Main Business Overview
13.10.5 Viamet Pharmaceuticals Inc Latest Developments
13.11 Vyome Biosciences Pvt Ltd
13.11.1 Vyome Biosciences Pvt Ltd Company Information
13.11.2 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolios and Specifications
13.11.3 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Vyome Biosciences Pvt Ltd Main Business Overview
13.11.5 Vyome Biosciences Pvt Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Dermatomycoses Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Dermatomycoses Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of BB-2603
Table 4. Major Players of Clotrimazole
Table 5. Major Players of Dapaconazole
Table 6. Major Players of Others
Table 7. Global Dermatomycoses Drug Sales byType (2020-2025) & (K Units)
Table 8. Global Dermatomycoses Drug Sales Market Share byType (2020-2025)
Table 9. Global Dermatomycoses Drug Revenue byType (2020-2025) & ($ million)
Table 10. Global Dermatomycoses Drug Revenue Market Share byType (2020-2025)
Table 11. Global Dermatomycoses Drug Sale Price byType (2020-2025) & (USD/Unit)
Table 12. Global Dermatomycoses Drug Sale by Application (2020-2025) & (K Units)
Table 13. Global Dermatomycoses Drug Sale Market Share by Application (2020-2025)
Table 14. Global Dermatomycoses Drug Revenue by Application (2020-2025) & ($ million)
Table 15. Global Dermatomycoses Drug Revenue Market Share by Application (2020-2025)
Table 16. Global Dermatomycoses Drug Sale Price by Application (2020-2025) & (USD/Unit)
Table 17. Global Dermatomycoses Drug Sales by Company (2020-2025) & (K Units)
Table 18. Global Dermatomycoses Drug Sales Market Share by Company (2020-2025)
Table 19. Global Dermatomycoses Drug Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Dermatomycoses Drug Revenue Market Share by Company (2020-2025)
Table 21. Global Dermatomycoses Drug Sale Price by Company (2020-2025) & (USD/Unit)
Table 22. Key Manufacturers Dermatomycoses Drug Producing Area Distribution and Sales Area
Table 23. Players Dermatomycoses Drug Products Offered
Table 24. Dermatomycoses Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Dermatomycoses Drug Sales by Geographic Region (2020-2025) & (K Units)
Table 28. Global Dermatomycoses Drug Sales Market Share Geographic Region (2020-2025)
Table 29. Global Dermatomycoses Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Dermatomycoses Drug Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Dermatomycoses Drug Sales by Country/Region (2020-2025) & (K Units)
Table 32. Global Dermatomycoses Drug Sales Market Share by Country/Region (2020-2025)
Table 33. Global Dermatomycoses Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Dermatomycoses Drug Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Dermatomycoses Drug Sales by Country (2020-2025) & (K Units)
Table 36. Americas Dermatomycoses Drug Sales Market Share by Country (2020-2025)
Table 37. Americas Dermatomycoses Drug Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Dermatomycoses Drug Sales byType (2020-2025) & (K Units)
Table 39. Americas Dermatomycoses Drug Sales by Application (2020-2025) & (K Units)
Table 40. APAC Dermatomycoses Drug Sales by Region (2020-2025) & (K Units)
Table 41. APAC Dermatomycoses Drug Sales Market Share by Region (2020-2025)
Table 42. APAC Dermatomycoses Drug Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Dermatomycoses Drug Sales byType (2020-2025) & (K Units)
Table 44. APAC Dermatomycoses Drug Sales by Application (2020-2025) & (K Units)
Table 45. Europe Dermatomycoses Drug Sales by Country (2020-2025) & (K Units)
Table 46. Europe Dermatomycoses Drug Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Dermatomycoses Drug Sales byType (2020-2025) & (K Units)
Table 48. Europe Dermatomycoses Drug Sales by Application (2020-2025) & (K Units)
Table 49. Middle East & Africa Dermatomycoses Drug Sales by Country (2020-2025) & (K Units)
Table 50. Middle East & Africa Dermatomycoses Drug Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Dermatomycoses Drug Sales byType (2020-2025) & (K Units)
Table 52. Middle East & Africa Dermatomycoses Drug Sales by Application (2020-2025) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Dermatomycoses Drug
Table 54. Key Market Challenges & Risks of Dermatomycoses Drug
Table 55. Key IndustryTrends of Dermatomycoses Drug
Table 56. Dermatomycoses Drug Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Dermatomycoses Drug Distributors List
Table 59. Dermatomycoses Drug Customer List
Table 60. Global Dermatomycoses Drug SalesForecast by Region (2026-2031) & (K Units)
Table 61. Global Dermatomycoses Drug RevenueForecast by Region (2026-2031) & ($ millions)
Table 62. Americas Dermatomycoses Drug SalesForecast by Country (2026-2031) & (K Units)
Table 63. Americas Dermatomycoses Drug Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 64. APAC Dermatomycoses Drug SalesForecast by Region (2026-2031) & (K Units)
Table 65. APAC Dermatomycoses Drug Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Europe Dermatomycoses Drug SalesForecast by Country (2026-2031) & (K Units)
Table 67. Europe Dermatomycoses Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa Dermatomycoses Drug SalesForecast by Country (2026-2031) & (K Units)
Table 69. Middle East & Africa Dermatomycoses Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Global Dermatomycoses Drug SalesForecast byType (2026-2031) & (K Units)
Table 71. Global Dermatomycoses Drug RevenueForecast byType (2026-2031) & ($ millions)
Table 72. Global Dermatomycoses Drug SalesForecast by Application (2026-2031) & (K Units)
Table 73. Global Dermatomycoses Drug RevenueForecast by Application (2026-2031) & ($ millions)
Table 74. Anacor Pharmaceuticals Inc Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 75. Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolios and Specifications
Table 76. Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. Anacor Pharmaceuticals Inc Main Business
Table 78. Anacor Pharmaceuticals Inc Latest Developments
Table 79. BiolabFarmaceutica Ltda Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. BiolabFarmaceutica Ltda Dermatomycoses Drug Product Portfolios and Specifications
Table 81. BiolabFarmaceutica Ltda Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 82. BiolabFarmaceutica Ltda Main Business
Table 83. BiolabFarmaceutica Ltda Latest Developments
Table 84. BlueberryTherapeutics Ltd Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 85. BlueberryTherapeutics Ltd Dermatomycoses Drug Product Portfolios and Specifications
Table 86. BlueberryTherapeutics Ltd Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 87. BlueberryTherapeutics Ltd Main Business
Table 88. BlueberryTherapeutics Ltd Latest Developments
Table 89. Daewoong Pharmaceutical Co Ltd Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolios and Specifications
Table 91. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 92. Daewoong Pharmaceutical Co Ltd Main Business
Table 93. Daewoong Pharmaceutical Co Ltd Latest Developments
Table 94. Dermala Inc Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Dermala Inc Dermatomycoses Drug Product Portfolios and Specifications
Table 96. Dermala Inc Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 97. Dermala Inc Main Business
Table 98. Dermala Inc Latest Developments
Table 99. Helix BioMedix Inc Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Helix BioMedix Inc Dermatomycoses Drug Product Portfolios and Specifications
Table 101. Helix BioMedix Inc Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 102. Helix BioMedix Inc Main Business
Table 103. Helix BioMedix Inc Latest Developments
Table 104. Novan Inc Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. Novan Inc Dermatomycoses Drug Product Portfolios and Specifications
Table 106. Novan Inc Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 107. Novan Inc Main Business
Table 108. Novan Inc Latest Developments
Table 109. Sol-GelTechnologies Ltd Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Sol-GelTechnologies Ltd Dermatomycoses Drug Product Portfolios and Specifications
Table 111. Sol-GelTechnologies Ltd Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 112. Sol-GelTechnologies Ltd Main Business
Table 113. Sol-GelTechnologies Ltd Latest Developments
Table 114.TGV-Laboratories Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 115.TGV-Laboratories Dermatomycoses Drug Product Portfolios and Specifications
Table 116.TGV-Laboratories Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 117.TGV-Laboratories Main Business
Table 118.TGV-Laboratories Latest Developments
Table 119. Viamet Pharmaceuticals Inc Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 120. Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolios and Specifications
Table 121. Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 122. Viamet Pharmaceuticals Inc Main Business
Table 123. Viamet Pharmaceuticals Inc Latest Developments
Table 124. Vyome Biosciences Pvt Ltd Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 125. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolios and Specifications
Table 126. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 127. Vyome Biosciences Pvt Ltd Main Business
Table 128. Vyome Biosciences Pvt Ltd Latest Developments
LIST OFFIGURES
Figure 1. Picture of Dermatomycoses Drug
Figure 2. Dermatomycoses Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Dermatomycoses Drug Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Dermatomycoses Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Dermatomycoses Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Dermatomycoses Drug Sales Market Share by Country/Region (2024)
Figure 10. Dermatomycoses Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of BB-2603
Figure 12. Product Picture of Clotrimazole
Figure 13. Product Picture of Dapaconazole
Figure 14. Product Picture of Others
Figure 15. Global Dermatomycoses Drug Sales Market Share byType in 2025
Figure 16. Global Dermatomycoses Drug Revenue Market Share byType (2020-2025)
Figure 17. Dermatomycoses Drug Consumed in Hospital
Figure 18. Global Dermatomycoses Drug Market: Hospital (2020-2025) & (K Units)
Figure 19. Dermatomycoses Drug Consumed in Clinic
Figure 20. Global Dermatomycoses Drug Market: Clinic (2020-2025) & (K Units)
Figure 21. Dermatomycoses Drug Consumed in Others
Figure 22. Global Dermatomycoses Drug Market: Others (2020-2025) & (K Units)
Figure 23. Global Dermatomycoses Drug Sale Market Share by Application (2024)
Figure 24. Global Dermatomycoses Drug Revenue Market Share by Application in 2025
Figure 25. Dermatomycoses Drug Sales by Company in 2025 (K Units)
Figure 26. Global Dermatomycoses Drug Sales Market Share by Company in 2025
Figure 27. Dermatomycoses Drug Revenue by Company in 2025 ($ millions)
Figure 28. Global Dermatomycoses Drug Revenue Market Share by Company in 2025
Figure 29. Global Dermatomycoses Drug Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Dermatomycoses Drug Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Dermatomycoses Drug Sales 2020-2025 (K Units)
Figure 32. Americas Dermatomycoses Drug Revenue 2020-2025 ($ millions)
Figure 33. APAC Dermatomycoses Drug Sales 2020-2025 (K Units)
Figure 34. APAC Dermatomycoses Drug Revenue 2020-2025 ($ millions)
Figure 35. Europe Dermatomycoses Drug Sales 2020-2025 (K Units)
Figure 36. Europe Dermatomycoses Drug Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Dermatomycoses Drug Sales 2020-2025 (K Units)
Figure 38. Middle East & Africa Dermatomycoses Drug Revenue 2020-2025 ($ millions)
Figure 39. Americas Dermatomycoses Drug Sales Market Share by Country in 2025
Figure 40. Americas Dermatomycoses Drug Revenue Market Share by Country (2020-2025)
Figure 41. Americas Dermatomycoses Drug Sales Market Share byType (2020-2025)
Figure 42. Americas Dermatomycoses Drug Sales Market Share by Application (2020-2025)
Figure 43. United States Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Dermatomycoses Drug Sales Market Share by Region in 2025
Figure 48. APAC Dermatomycoses Drug Revenue Market Share by Region (2020-2025)
Figure 49. APAC Dermatomycoses Drug Sales Market Share byType (2020-2025)
Figure 50. APAC Dermatomycoses Drug Sales Market Share by Application (2020-2025)
Figure 51. China Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. India Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. ChinaTaiwan Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Dermatomycoses Drug Sales Market Share by Country in 2025
Figure 59. Europe Dermatomycoses Drug Revenue Market Share by Country (2020-2025)
Figure 60. Europe Dermatomycoses Drug Sales Market Share byType (2020-2025)
Figure 61. Europe Dermatomycoses Drug Sales Market Share by Application (2020-2025)
Figure 62. Germany Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 63.France Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Dermatomycoses Drug Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Dermatomycoses Drug Sales Market Share byType (2020-2025)
Figure 69. Middle East & Africa Dermatomycoses Drug Sales Market Share by Application (2020-2025)
Figure 70. Egypt Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 73.Turkey Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Dermatomycoses Drug in 2025
Figure 76. Manufacturing Process Analysis of Dermatomycoses Drug
Figure 77. Industry Chain Structure of Dermatomycoses Drug
Figure 78. Channels of Distribution
Figure 79. Global Dermatomycoses Drug Sales MarketForecast by Region (2026-2031)
Figure 80. Global Dermatomycoses Drug Revenue Market ShareForecast by Region (2026-2031)
Figure 81. Global Dermatomycoses Drug Sales Market ShareForecast byType (2026-2031)
Figure 82. Global Dermatomycoses Drug Revenue Market ShareForecast byType (2026-2031)
Figure 83. Global Dermatomycoses Drug Sales Market ShareForecast by Application (2026-2031)
Figure 84. Global Dermatomycoses Drug Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Dermatomycoses Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Dermatomycoses Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Dermatomycoses Drug by Country/Region, 2020, 2024 & 2031
2.2 Dermatomycoses Drug Segment by Type
2.2.1 BB-2603
2.2.2 Clotrimazole
2.2.3 Dapaconazole
2.2.4 Others
2.3 Dermatomycoses Drug Sales by Type
2.3.1 Global Dermatomycoses Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Dermatomycoses Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Dermatomycoses Drug Sale Price by Type (2020-2025)
2.4 Dermatomycoses Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Dermatomycoses Drug Sales by Application
2.5.1 Global Dermatomycoses Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Dermatomycoses Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Dermatomycoses Drug Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Dermatomycoses Drug Breakdown Data by Company
3.1.1 Global Dermatomycoses Drug Annual Sales by Company (2020-2025)
3.1.2 Global Dermatomycoses Drug Sales Market Share by Company (2020-2025)
3.2 Global Dermatomycoses Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Dermatomycoses Drug Revenue by Company (2020-2025)
3.2.2 Global Dermatomycoses Drug Revenue Market Share by Company (2020-2025)
3.3 Global Dermatomycoses Drug Sale Price by Company
3.4 Key Manufacturers Dermatomycoses Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Dermatomycoses Drug Product Location Distribution
3.4.2 Players Dermatomycoses Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DERMATOMYCOSES DRUG BY GEOGRAPHIC REGION
4.1 World Historic Dermatomycoses Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Dermatomycoses Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Dermatomycoses Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Dermatomycoses Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Dermatomycoses Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Dermatomycoses Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Dermatomycoses Drug Sales Growth
4.4 APAC Dermatomycoses Drug Sales Growth
4.5 Europe Dermatomycoses Drug Sales Growth
4.6 Middle East & Africa Dermatomycoses Drug Sales Growth
5 AMERICAS
5.1 Americas Dermatomycoses Drug Sales by Country
5.1.1 Americas Dermatomycoses Drug Sales by Country (2020-2025)
5.1.2 Americas Dermatomycoses Drug Revenue by Country (2020-2025)
5.2 Americas Dermatomycoses Drug Sales by Type (2020-2025)
5.3 Americas Dermatomycoses Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Dermatomycoses Drug Sales by Region
6.1.1 APAC Dermatomycoses Drug Sales by Region (2020-2025)
6.1.2 APAC Dermatomycoses Drug Revenue by Region (2020-2025)
6.2 APAC Dermatomycoses Drug Sales by Type (2020-2025)
6.3 APAC Dermatomycoses Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Dermatomycoses Drug by Country
7.1.1 Europe Dermatomycoses Drug Sales by Country (2020-2025)
7.1.2 Europe Dermatomycoses Drug Revenue by Country (2020-2025)
7.2 Europe Dermatomycoses Drug Sales by Type (2020-2025)
7.3 Europe Dermatomycoses Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Dermatomycoses Drug by Country
8.1.1 Middle East & Africa Dermatomycoses Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Dermatomycoses Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Dermatomycoses Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Dermatomycoses Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Dermatomycoses Drug
10.3 Manufacturing Process Analysis of Dermatomycoses Drug
10.4 Industry Chain Structure of Dermatomycoses Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Dermatomycoses Drug Distributors
11.3 Dermatomycoses Drug Customer
12 WORLD FORECAST REVIEW FOR DERMATOMYCOSES DRUG BY GEOGRAPHIC REGION
12.1 Global Dermatomycoses Drug Market Size Forecast by Region
12.1.1 Global Dermatomycoses Drug Forecast by Region (2026-2031)
12.1.2 Global Dermatomycoses Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Dermatomycoses Drug Forecast by Type (2026-2031)
12.7 Global Dermatomycoses Drug Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Anacor Pharmaceuticals Inc
13.1.1 Anacor Pharmaceuticals Inc Company Information
13.1.2 Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolios and Specifications
13.1.3 Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Anacor Pharmaceuticals Inc Main Business Overview
13.1.5 Anacor Pharmaceuticals Inc Latest Developments
13.2 Biolab Farmaceutica Ltda
13.2.1 Biolab Farmaceutica Ltda Company Information
13.2.2 Biolab Farmaceutica Ltda Dermatomycoses Drug Product Portfolios and Specifications
13.2.3 Biolab Farmaceutica Ltda Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Biolab Farmaceutica Ltda Main Business Overview
13.2.5 Biolab Farmaceutica Ltda Latest Developments
13.3 Blueberry Therapeutics Ltd
13.3.1 Blueberry Therapeutics Ltd Company Information
13.3.2 Blueberry Therapeutics Ltd Dermatomycoses Drug Product Portfolios and Specifications
13.3.3 Blueberry Therapeutics Ltd Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Blueberry Therapeutics Ltd Main Business Overview
13.3.5 Blueberry Therapeutics Ltd Latest Developments
13.4 Daewoong Pharmaceutical Co Ltd
13.4.1 Daewoong Pharmaceutical Co Ltd Company Information
13.4.2 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolios and Specifications
13.4.3 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Daewoong Pharmaceutical Co Ltd Main Business Overview
13.4.5 Daewoong Pharmaceutical Co Ltd Latest Developments
13.5 Dermala Inc
13.5.1 Dermala Inc Company Information
13.5.2 Dermala Inc Dermatomycoses Drug Product Portfolios and Specifications
13.5.3 Dermala Inc Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Dermala Inc Main Business Overview
13.5.5 Dermala Inc Latest Developments
13.6 Helix BioMedix Inc
13.6.1 Helix BioMedix Inc Company Information
13.6.2 Helix BioMedix Inc Dermatomycoses Drug Product Portfolios and Specifications
13.6.3 Helix BioMedix Inc Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Helix BioMedix Inc Main Business Overview
13.6.5 Helix BioMedix Inc Latest Developments
13.7 Novan Inc
13.7.1 Novan Inc Company Information
13.7.2 Novan Inc Dermatomycoses Drug Product Portfolios and Specifications
13.7.3 Novan Inc Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Novan Inc Main Business Overview
13.7.5 Novan Inc Latest Developments
13.8 Sol-Gel Technologies Ltd
13.8.1 Sol-Gel Technologies Ltd Company Information
13.8.2 Sol-Gel Technologies Ltd Dermatomycoses Drug Product Portfolios and Specifications
13.8.3 Sol-Gel Technologies Ltd Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Sol-Gel Technologies Ltd Main Business Overview
13.8.5 Sol-Gel Technologies Ltd Latest Developments
13.9 TGV-Laboratories
13.9.1 TGV-Laboratories Company Information
13.9.2 TGV-Laboratories Dermatomycoses Drug Product Portfolios and Specifications
13.9.3 TGV-Laboratories Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 TGV-Laboratories Main Business Overview
13.9.5 TGV-Laboratories Latest Developments
13.10 Viamet Pharmaceuticals Inc
13.10.1 Viamet Pharmaceuticals Inc Company Information
13.10.2 Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolios and Specifications
13.10.3 Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Viamet Pharmaceuticals Inc Main Business Overview
13.10.5 Viamet Pharmaceuticals Inc Latest Developments
13.11 Vyome Biosciences Pvt Ltd
13.11.1 Vyome Biosciences Pvt Ltd Company Information
13.11.2 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolios and Specifications
13.11.3 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Vyome Biosciences Pvt Ltd Main Business Overview
13.11.5 Vyome Biosciences Pvt Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Dermatomycoses Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Dermatomycoses Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of BB-2603
Table 4. Major Players of Clotrimazole
Table 5. Major Players of Dapaconazole
Table 6. Major Players of Others
Table 7. Global Dermatomycoses Drug Sales byType (2020-2025) & (K Units)
Table 8. Global Dermatomycoses Drug Sales Market Share byType (2020-2025)
Table 9. Global Dermatomycoses Drug Revenue byType (2020-2025) & ($ million)
Table 10. Global Dermatomycoses Drug Revenue Market Share byType (2020-2025)
Table 11. Global Dermatomycoses Drug Sale Price byType (2020-2025) & (USD/Unit)
Table 12. Global Dermatomycoses Drug Sale by Application (2020-2025) & (K Units)
Table 13. Global Dermatomycoses Drug Sale Market Share by Application (2020-2025)
Table 14. Global Dermatomycoses Drug Revenue by Application (2020-2025) & ($ million)
Table 15. Global Dermatomycoses Drug Revenue Market Share by Application (2020-2025)
Table 16. Global Dermatomycoses Drug Sale Price by Application (2020-2025) & (USD/Unit)
Table 17. Global Dermatomycoses Drug Sales by Company (2020-2025) & (K Units)
Table 18. Global Dermatomycoses Drug Sales Market Share by Company (2020-2025)
Table 19. Global Dermatomycoses Drug Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Dermatomycoses Drug Revenue Market Share by Company (2020-2025)
Table 21. Global Dermatomycoses Drug Sale Price by Company (2020-2025) & (USD/Unit)
Table 22. Key Manufacturers Dermatomycoses Drug Producing Area Distribution and Sales Area
Table 23. Players Dermatomycoses Drug Products Offered
Table 24. Dermatomycoses Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Dermatomycoses Drug Sales by Geographic Region (2020-2025) & (K Units)
Table 28. Global Dermatomycoses Drug Sales Market Share Geographic Region (2020-2025)
Table 29. Global Dermatomycoses Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Dermatomycoses Drug Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Dermatomycoses Drug Sales by Country/Region (2020-2025) & (K Units)
Table 32. Global Dermatomycoses Drug Sales Market Share by Country/Region (2020-2025)
Table 33. Global Dermatomycoses Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Dermatomycoses Drug Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Dermatomycoses Drug Sales by Country (2020-2025) & (K Units)
Table 36. Americas Dermatomycoses Drug Sales Market Share by Country (2020-2025)
Table 37. Americas Dermatomycoses Drug Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Dermatomycoses Drug Sales byType (2020-2025) & (K Units)
Table 39. Americas Dermatomycoses Drug Sales by Application (2020-2025) & (K Units)
Table 40. APAC Dermatomycoses Drug Sales by Region (2020-2025) & (K Units)
Table 41. APAC Dermatomycoses Drug Sales Market Share by Region (2020-2025)
Table 42. APAC Dermatomycoses Drug Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Dermatomycoses Drug Sales byType (2020-2025) & (K Units)
Table 44. APAC Dermatomycoses Drug Sales by Application (2020-2025) & (K Units)
Table 45. Europe Dermatomycoses Drug Sales by Country (2020-2025) & (K Units)
Table 46. Europe Dermatomycoses Drug Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Dermatomycoses Drug Sales byType (2020-2025) & (K Units)
Table 48. Europe Dermatomycoses Drug Sales by Application (2020-2025) & (K Units)
Table 49. Middle East & Africa Dermatomycoses Drug Sales by Country (2020-2025) & (K Units)
Table 50. Middle East & Africa Dermatomycoses Drug Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Dermatomycoses Drug Sales byType (2020-2025) & (K Units)
Table 52. Middle East & Africa Dermatomycoses Drug Sales by Application (2020-2025) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Dermatomycoses Drug
Table 54. Key Market Challenges & Risks of Dermatomycoses Drug
Table 55. Key IndustryTrends of Dermatomycoses Drug
Table 56. Dermatomycoses Drug Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Dermatomycoses Drug Distributors List
Table 59. Dermatomycoses Drug Customer List
Table 60. Global Dermatomycoses Drug SalesForecast by Region (2026-2031) & (K Units)
Table 61. Global Dermatomycoses Drug RevenueForecast by Region (2026-2031) & ($ millions)
Table 62. Americas Dermatomycoses Drug SalesForecast by Country (2026-2031) & (K Units)
Table 63. Americas Dermatomycoses Drug Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 64. APAC Dermatomycoses Drug SalesForecast by Region (2026-2031) & (K Units)
Table 65. APAC Dermatomycoses Drug Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Europe Dermatomycoses Drug SalesForecast by Country (2026-2031) & (K Units)
Table 67. Europe Dermatomycoses Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa Dermatomycoses Drug SalesForecast by Country (2026-2031) & (K Units)
Table 69. Middle East & Africa Dermatomycoses Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Global Dermatomycoses Drug SalesForecast byType (2026-2031) & (K Units)
Table 71. Global Dermatomycoses Drug RevenueForecast byType (2026-2031) & ($ millions)
Table 72. Global Dermatomycoses Drug SalesForecast by Application (2026-2031) & (K Units)
Table 73. Global Dermatomycoses Drug RevenueForecast by Application (2026-2031) & ($ millions)
Table 74. Anacor Pharmaceuticals Inc Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 75. Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolios and Specifications
Table 76. Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. Anacor Pharmaceuticals Inc Main Business
Table 78. Anacor Pharmaceuticals Inc Latest Developments
Table 79. BiolabFarmaceutica Ltda Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. BiolabFarmaceutica Ltda Dermatomycoses Drug Product Portfolios and Specifications
Table 81. BiolabFarmaceutica Ltda Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 82. BiolabFarmaceutica Ltda Main Business
Table 83. BiolabFarmaceutica Ltda Latest Developments
Table 84. BlueberryTherapeutics Ltd Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 85. BlueberryTherapeutics Ltd Dermatomycoses Drug Product Portfolios and Specifications
Table 86. BlueberryTherapeutics Ltd Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 87. BlueberryTherapeutics Ltd Main Business
Table 88. BlueberryTherapeutics Ltd Latest Developments
Table 89. Daewoong Pharmaceutical Co Ltd Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolios and Specifications
Table 91. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 92. Daewoong Pharmaceutical Co Ltd Main Business
Table 93. Daewoong Pharmaceutical Co Ltd Latest Developments
Table 94. Dermala Inc Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Dermala Inc Dermatomycoses Drug Product Portfolios and Specifications
Table 96. Dermala Inc Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 97. Dermala Inc Main Business
Table 98. Dermala Inc Latest Developments
Table 99. Helix BioMedix Inc Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Helix BioMedix Inc Dermatomycoses Drug Product Portfolios and Specifications
Table 101. Helix BioMedix Inc Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 102. Helix BioMedix Inc Main Business
Table 103. Helix BioMedix Inc Latest Developments
Table 104. Novan Inc Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. Novan Inc Dermatomycoses Drug Product Portfolios and Specifications
Table 106. Novan Inc Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 107. Novan Inc Main Business
Table 108. Novan Inc Latest Developments
Table 109. Sol-GelTechnologies Ltd Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Sol-GelTechnologies Ltd Dermatomycoses Drug Product Portfolios and Specifications
Table 111. Sol-GelTechnologies Ltd Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 112. Sol-GelTechnologies Ltd Main Business
Table 113. Sol-GelTechnologies Ltd Latest Developments
Table 114.TGV-Laboratories Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 115.TGV-Laboratories Dermatomycoses Drug Product Portfolios and Specifications
Table 116.TGV-Laboratories Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 117.TGV-Laboratories Main Business
Table 118.TGV-Laboratories Latest Developments
Table 119. Viamet Pharmaceuticals Inc Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 120. Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolios and Specifications
Table 121. Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 122. Viamet Pharmaceuticals Inc Main Business
Table 123. Viamet Pharmaceuticals Inc Latest Developments
Table 124. Vyome Biosciences Pvt Ltd Basic Information, Dermatomycoses Drug Manufacturing Base, Sales Area and Its Competitors
Table 125. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolios and Specifications
Table 126. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 127. Vyome Biosciences Pvt Ltd Main Business
Table 128. Vyome Biosciences Pvt Ltd Latest Developments
LIST OFFIGURES
Figure 1. Picture of Dermatomycoses Drug
Figure 2. Dermatomycoses Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Dermatomycoses Drug Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Dermatomycoses Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Dermatomycoses Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Dermatomycoses Drug Sales Market Share by Country/Region (2024)
Figure 10. Dermatomycoses Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of BB-2603
Figure 12. Product Picture of Clotrimazole
Figure 13. Product Picture of Dapaconazole
Figure 14. Product Picture of Others
Figure 15. Global Dermatomycoses Drug Sales Market Share byType in 2025
Figure 16. Global Dermatomycoses Drug Revenue Market Share byType (2020-2025)
Figure 17. Dermatomycoses Drug Consumed in Hospital
Figure 18. Global Dermatomycoses Drug Market: Hospital (2020-2025) & (K Units)
Figure 19. Dermatomycoses Drug Consumed in Clinic
Figure 20. Global Dermatomycoses Drug Market: Clinic (2020-2025) & (K Units)
Figure 21. Dermatomycoses Drug Consumed in Others
Figure 22. Global Dermatomycoses Drug Market: Others (2020-2025) & (K Units)
Figure 23. Global Dermatomycoses Drug Sale Market Share by Application (2024)
Figure 24. Global Dermatomycoses Drug Revenue Market Share by Application in 2025
Figure 25. Dermatomycoses Drug Sales by Company in 2025 (K Units)
Figure 26. Global Dermatomycoses Drug Sales Market Share by Company in 2025
Figure 27. Dermatomycoses Drug Revenue by Company in 2025 ($ millions)
Figure 28. Global Dermatomycoses Drug Revenue Market Share by Company in 2025
Figure 29. Global Dermatomycoses Drug Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Dermatomycoses Drug Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Dermatomycoses Drug Sales 2020-2025 (K Units)
Figure 32. Americas Dermatomycoses Drug Revenue 2020-2025 ($ millions)
Figure 33. APAC Dermatomycoses Drug Sales 2020-2025 (K Units)
Figure 34. APAC Dermatomycoses Drug Revenue 2020-2025 ($ millions)
Figure 35. Europe Dermatomycoses Drug Sales 2020-2025 (K Units)
Figure 36. Europe Dermatomycoses Drug Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Dermatomycoses Drug Sales 2020-2025 (K Units)
Figure 38. Middle East & Africa Dermatomycoses Drug Revenue 2020-2025 ($ millions)
Figure 39. Americas Dermatomycoses Drug Sales Market Share by Country in 2025
Figure 40. Americas Dermatomycoses Drug Revenue Market Share by Country (2020-2025)
Figure 41. Americas Dermatomycoses Drug Sales Market Share byType (2020-2025)
Figure 42. Americas Dermatomycoses Drug Sales Market Share by Application (2020-2025)
Figure 43. United States Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Dermatomycoses Drug Sales Market Share by Region in 2025
Figure 48. APAC Dermatomycoses Drug Revenue Market Share by Region (2020-2025)
Figure 49. APAC Dermatomycoses Drug Sales Market Share byType (2020-2025)
Figure 50. APAC Dermatomycoses Drug Sales Market Share by Application (2020-2025)
Figure 51. China Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. India Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. ChinaTaiwan Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Dermatomycoses Drug Sales Market Share by Country in 2025
Figure 59. Europe Dermatomycoses Drug Revenue Market Share by Country (2020-2025)
Figure 60. Europe Dermatomycoses Drug Sales Market Share byType (2020-2025)
Figure 61. Europe Dermatomycoses Drug Sales Market Share by Application (2020-2025)
Figure 62. Germany Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 63.France Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Dermatomycoses Drug Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Dermatomycoses Drug Sales Market Share byType (2020-2025)
Figure 69. Middle East & Africa Dermatomycoses Drug Sales Market Share by Application (2020-2025)
Figure 70. Egypt Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 73.Turkey Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Dermatomycoses Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Dermatomycoses Drug in 2025
Figure 76. Manufacturing Process Analysis of Dermatomycoses Drug
Figure 77. Industry Chain Structure of Dermatomycoses Drug
Figure 78. Channels of Distribution
Figure 79. Global Dermatomycoses Drug Sales MarketForecast by Region (2026-2031)
Figure 80. Global Dermatomycoses Drug Revenue Market ShareForecast by Region (2026-2031)
Figure 81. Global Dermatomycoses Drug Sales Market ShareForecast byType (2026-2031)
Figure 82. Global Dermatomycoses Drug Revenue Market ShareForecast byType (2026-2031)
Figure 83. Global Dermatomycoses Drug Sales Market ShareForecast by Application (2026-2031)
Figure 84. Global Dermatomycoses Drug Revenue Market ShareForecast by Application (2026-2031)
More Publications
Global Shoe Making Machine Market Growth 2024-2030
US$ 3,660.00
August 2024
107 pages
Global Shrink Sleeve Labeling Equipment Market Growth 2023-2029
US$ 3,660.00
March 2023
110 pages
Global Track Pin Seals Market Growth 2025-2031
US$ 3,660.00
February 2025
109 pages
Global Medical Tubing Cutter Market Growth 2023-2029
US$ 3,660.00
January 2023
108 pages
Global Commercial IC Card Gas Smart Meter Market Growth 2023-2029
US$ 3,660.00
March 2023
121 pages
